Capricor Therapeutics (CAPR) Operating Income (2016 - 2025)
Historic Operating Income for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$26.3 million.
- Capricor Therapeutics' Operating Income fell 10203.14% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.7 million, marking a year-over-year decrease of 10667.89%. This contributed to the annual value of -$42.6 million for FY2024, which is 7678.0% down from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' Operating Income is -$26.3 million, which was down 10203.14% from -$27.7 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Operating Income registered a high of -$1.3 million during Q4 2023, and its lowest value of -$27.7 million during Q2 2025.
- Its 5-year average for Operating Income is -$9.8 million, with a median of -$7.7 million in 2023.
- As far as peak fluctuations go, Capricor Therapeutics' Operating Income soared by 8411.56% in 2023, and later crashed by 50078.74% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' Operating Income stood at -$6.4 million in 2021, then decreased by 26.44% to -$8.1 million in 2022, then surged by 84.12% to -$1.3 million in 2023, then plummeted by 500.79% to -$7.7 million in 2024, then tumbled by 241.45% to -$26.3 million in 2025.
- Its last three reported values are -$26.3 million in Q3 2025, -$27.7 million for Q2 2025, and -$7.7 million during Q4 2024.